Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

SCLX

Scilex (SCLX)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SCLX
DataOraFonteTitoloSimboloCompagnia
31/01/202515:00GlobeNewswire Inc.Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025NASDAQ:SCLXScilex Holding Company
22/01/202514:00GlobeNewswire Inc.Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain IndicationNASDAQ:SCLXScilex Holding Company
21/01/202517:49GlobeNewswire Inc.Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)NASDAQ:SCLXScilex Holding Company
21/01/202515:46GlobeNewswire Inc.Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025NASDAQ:SCLXScilex Holding Company
21/01/202515:00GlobeNewswire Inc.Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLCNASDAQ:SCLXScilex Holding Company
21/01/202513:00GlobeNewswire Inc.Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain IndicationNASDAQ:SCLXScilex Holding Company
21/01/202512:00GlobeNewswire Inc.Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024NASDAQ:SCLXScilex Holding Company
16/01/202521:38GlobeNewswire Inc.Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in AdultsNASDAQ:SCLXScilex Holding Company
13/01/202515:00GlobeNewswire Inc.Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% PatchNASDAQ:SCLXScilex Holding Company
08/01/202522:00GlobeNewswire Inc.Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business CombinationNASDAQ:SCLXScilex Holding Company
30/12/202415:00GlobeNewswire Inc.Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 tNASDAQ:SCLXScilex Holding Company
16/12/202415:00GlobeNewswire Inc.Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationNASDAQ:SCLXScilex Holding Company
13/12/202418:23GlobeNewswire Inc.Scilex Holding Company Announces Closing of $17 Million Registered Direct OfferingNASDAQ:SCLXScilex Holding Company
12/12/202414:21GlobeNewswire Inc.Scilex Holding Company Announces $17 Million Registered Direct OfferingNASDAQ:SCLXScilex Holding Company
11/12/202418:49GlobeNewswire Inc.Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025NASDAQ:SCLXScilex Holding Company
11/12/202413:30GlobeNewswire Inc.Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 TrialNASDAQ:SCLXScilex Holding Company
10/12/202413:00GlobeNewswire Inc.Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and NeuroNASDAQ:SCLXScilex Holding Company
22/11/202412:00GlobeNewswire Inc.Scilex Holding Company Announces Receipt of Notice from NasdaqNASDAQ:SCLXScilex Holding Company
15/11/202415:00GlobeNewswire Inc.Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024NASDAQ:SCLXScilex Holding Company
06/11/202418:24GlobeNewswire Inc.Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the PreviouslyNASDAQ:SCLXScilex Holding Company
30/10/202411:00GlobeNewswire Inc.Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (LNASDAQ:SCLXScilex Holding Company
29/10/202411:00GlobeNewswire Inc.Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common StockNASDAQ:SCLXScilex Holding Company
28/10/202411:00GlobeNewswire Inc.Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned SubsidiaryNASDAQ:SCLXScilex Holding Company
16/10/202419:40AllPennyStocks.comHolding Company Shares Rally Following Board Of Directors CommentaryNASDAQ:SCLXScilex Holding Company
16/10/202413:00GlobeNewswire Inc.Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securitiNASDAQ:SCLXScilex Holding Company
16/10/202410:00GlobeNewswire Inc.Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur aNASDAQ:SCLXScilex Holding Company
08/10/202419:58GlobeNewswire Inc.Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024NASDAQ:SCLXScilex Holding Company
08/10/202417:50GlobeNewswire Inc.Scilex Holding Company Announces Closing of a $50 Million Registered Convertible FinancingNASDAQ:SCLXScilex Holding Company
07/10/202415:52GlobeNewswire Inc.Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial ProfileNASDAQ:SCLXScilex Holding Company
26/09/202415:00GlobeNewswire Inc.Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025NASDAQ:SCLXScilex Holding Company
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SCLX
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network